TNFRSF1A and metabolic dysfunction-associated steatotic liver disease: The extent of fibrosis, analyzed by Sirius Red staining, was clearly reduced in anti-TNFR1-treated compared to control-Ab-treated NAFLD mice (Fig. 3a).